Explore VELSIPITY

style

section-heading, mw-930, bg-color-stratos, heading-with-des

VELSIPITY is a next-generation S1P receptor modulator

VELSIPITY safety and efficacy was studied in people with moderate to severe UC across 2 different clinical trials, one lasting 3 months and the other 1 year. These trials looked at the safety and efficacy of VELSIPITY in treating UC, including when conventional therapies like 5-ASAs* or steroids weren't working.

VELSIPITY was studied in 495 people in two clinical trials:

In the 3-month study:

221 On VELSIPITY

112 On PLACEBO

Average age was 41 years
41% female participants

In the 12-month study:

274 On VELSIPITY

134 On PLACEBO

Average age was 41 years
45% female participants

*5-ASAs are 5-aminosalicylic acid derivatives.

In adults with moderate to severe UC

More people on VELSIPITY achieved clinical remission* in just 3 months.

In the 52-week trial, at 12 weeks: 27% of people achieved clinical remission on VELSIPITY vs 7% on placebo.
In the 12-week trial: 26% of people achieved clinical remission on VELSIPITY vs 15% on placebo.

Creature hanging upside down

*Clinical remission means that the symptoms of the disease have improved or disappeared. During remission, you may experience fewer or no episodes of stool frequency and/or rectal bleeding. It’s important to remember that remission doesn’t mean you are cured, and you still need to follow your doctor’s advice to keep the disease under control and help prevent flare-ups.

Style

bg-white, pb-10, pb-tablet-16

VELSIPITY works fast to treat flares

Less frequent visits to the bathroom in 2 weeks

Some saw rapid relief from UC symptoms with less frequent visits to the bathroom at week 2 versus placebo.

Some people taking VELSIPITY for 4 weeks saw their UC-related bleeding start to improve versus placebo.

Style

bg-color-stratos, py-12, py-tablet-18

Visible normalization of the colon lining at 1 year

Visible normalization of the colon means that those areas of the colon lining assessed show no visible signs of inflammation or show the disease appears inactive with endoscopy. Areas visually assessed may not represent improvement of the entire colon lining.